CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a commercial-stage ...
Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region The SFDA ...
Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...
Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo ...
Agios Pharmaceuticals has filed for regulatory approval of its drug Mitapivat (PYRUKYND) to treat adult patients with both non-transfusion-dependent and transfusion-dependent forms of alpha- or ...
In the beta thalassemia study, Dr. de la Fuente and his colleagues used two quality of life scales to evaluate outcomes in adult patients and two quality of life scales for adolescent patients. Unlike ...
Stuart Orkin, the Harvard Medical School David G. Nathan Distinguished Professor of Pediatrics at Dana-Farber Cancer ...
Your blood carries oxygen to all of the cells in your body. When there are problems with red blood cells, you may feel weak and tired and may have to take medicines or receive blood transfusions to ...
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results